News
- 2025.08.12
- Notice Regarding the Completion of Payment for the Issue Price of the Issuance of the 65th to 67th Stock Acquisition Rights (with Exercise Price Adjustment Clauses) through Third-Party Allotment
- 2025.08.12
- Notice Regarding Adjustment of Conversion Price
- 2025.08.12
- Notice Regarding Adjustment of Exercise Price
- 2025.08.12
- SymBio Announces Abstract on Brincidofovir for the Treatment of Malignant Brain Tumors (Glioblastoma) Accepted for Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting to be Held in November 2025
- 2025.08.04
- 半期報告書－第21期(2025/01/01－2025/12/31) (Japanese only)
Selection News
- 2025.08.12
- 2025年12月期中間決算説明会の動画を掲載しました。(Japanese only)
- 2025.08.05
- 中間決算説明会資料（2025年12月期）(Japanese only)
- 2025.06.30
- 「ブリンシドフォビル開発最前線」を追加しました。
- 2025.06.03
- Key person interview: Updated the Page
- 2025.05.16
- 株主通信「SymBio VISION vol.27」(Japanese only)
- 2025.03.28
- 「動画で観るシンバイオ製薬」を更新しました。(Japanese only)
- 2025.03.28
- 第20期定時株主総会の動画を掲載しました。(Japanese only)
- 2025.02.26
- 2024年12月期決算説明会の動画を掲載しました。(Japanese only)
- 2025.02.13
- 決算説明会資料（2024年12月期）(Japanese only)
- 2024.08.13
- Article on 2024 1H Earnings Call Featured in Nikkei Biotech Online (Japanese only)
Source: Nikkei Biotech ONLINE, 2024.08.07
Although Nikkei BP grants permission to use the articles, the content of the articles does not constitute a recommendation to purchase/invest in a specific company/organization or product/service.
Unauthorized reproduction, duplication, or electronic storage of the articles/photos/charts, etc. is prohibited.
- 2023.11.17
- Notice of Relocation of Head Office